Occupational Therapists in Apalachin, NY Accepting Medicare
3 Occupational Therapists found. Showing 1 - 3
 Mrs. Kimberly M Mario Wiggins, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1971 Marshland Rd, Apalachin, NY 13732 Phone: 607-689-0922 |
Mrs. Carolyn Renee Barnett, MS OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 23 W Glann Rd, Apalachin, NY 13732 Phone: 607-725-0889 Fax: 607-625-4251 |
Gabrielle Irene Mead, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2479 S Apalachin Rd, Apalachin, NY 13732 Phone: 607-761-1158 |
News Archive
New highly-accurate blood test can measure all forms of vitamin D deficiencies
Researchers from London's Kingston University have developed a new highly-accurate blood test which can detect how much a patient's diet could be responsible for a lack of the so-called 'sunshine vitamin'. Vitamin D deficiencies can weaken the immune system and increase the risk of cancer and osteoporosis.
Roundup: States controlled by GOP pass sweeping changes; state budgets still very lean from recession; La. Gov. wrestling with legislature over spending
Republicans controlled all the levers of government in a staggering number of states this year — and it showed. Holding a lock on the governorship and both houses of the legislature in 20 states, GOP conservatives advanced an agenda that may change the face of state government for decades. They honored pledges not to raise taxes by enacting huge spending cuts to balance budgets in Florida and Texas.
Researchers develop new cocktail of drugs that shrink pancreatic tumors
Cancer is relentless and resilient. When a drug blocks a cancer cell's main survival pathway, the cell avoids the obstacle by taking different pathways or detours to save itself. This tactic is called "developing resistance," and it's one of the key challenges researchers face when seeking effective therapeutics to combat pancreatic ductal adenocarcinoma (PDA).
Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France
Promethera Biosciences, a Belgian biotechnology company developing Promethera(R) HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announced that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial.
› Verified 7 days ago
Physical Therapists
Speech-Language Pathologists
Occupational Therapists
Optometrists